Business Information
The group's principal activity is to develop, manufacture and sell branded prescription pharmaceutical products. The products are classified into cardiovascular including altace(R), corzide(R), procanbid(R) and thalitone(R) , endocrinology/women's health including levoxyl(R), cytomel(R), triostat(R) , prefest(R), menest(R), delestrogen(R) and nordette(R), neuroscience including sonata(R) and skelaxin(R), critical care including thrombin-jmi(R) , brevital(R) and synercid(R), anti-infectives including bicillin(R), cortisporin(R), neosporin(R) and coly-mycin m(R) and respiratory including intal(R) and tilade(r). They are marketed to general/family practitioners, internal medicine physicians, cardiologists, endocrinologists, obstetrician/gynecologists and hospitals across the unites states and Puerto Rico. On 08-Jun-2003 and on 12-Jun-2003, the group acquired meridian medical technologies inc and elan corporation plc respectively.
|
|
Name |
Title
|
Email
|
| Brian Markison | CEO, Pres. | N/A | | Eric Carter | Chief Science Officer | N/A | | Frederick Brouillette | Corporate Compliance Officer | N/A | | Joseph Squicciarino | CFO | N/A | | Rick Brouillette | Corporate Compliance Officer | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,988,500 | 288,949 | | 2005 | 1,772,881 | 117,833 | | 2004 | 1,304,364 | (160,288)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
